FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126528925> ?p ?o ?g. }

• W3126528925 endingPage "585" @default.
• W3126528925 startingPage "585" @default.
• W3126528925 abstract "Immune checkpoint inhibitors (ICIs) induce durable clinical responses only in a subset of advanced non-small cell lung cancer (NSCLC) patients. There is a need to identify mechanisms of ICI resistance and immunotherapy biomarkers to improve clinical benefit. In this study, we evaluated the prognostic and predictive value of circulating endothelial and leukocyte-derived extracellular vesicles (EV) in patients with advanced NSCLC treated with anti-PD-1/PD-L1 agents. In addition, the relationship between total blood circulating EV proteome and response to ICIs was investigated. An optimized flow cytometry method was employed for the identification and subtyping of blood circulating EVs in 59 patients with advanced NSCLC. Blood samples were collected from patients receiving anti-PD-1/PD-L1 inhibitors (n = 31) or chemotherapy (n = 28). An exploratory proteomic analysis of sorted blood EVs was conducted in a subset of patients. Our results show that a low blood concentration of circulating endothelial-derived EVs before treatment was strongly associated to longer overall survival (p = 0.0004) and higher disease control rate (p = 0.045) in patients treated with ICIs. Interestingly, shotgun proteomics revealed that EVs of responders to anti-PD-1 therapy had a specific protein cargo before treatment. In addition, EV protein cargo was specifically modulated during immunotherapy. We identified a previously unknown association between circulating endothelial-derived extracellular vesicle concentration and immunotherapy-related clinical outcomes. We also observed differences in circulating extracellular vesicle proteome according to anti-PD-1-based treatment response in NSCLC patients. Overall, these results may contribute to the identification of novel circulating biomarkers for rational immunotherapy approaches in patients affected by NSCLC." @default.
• W3126528925 created "2021-02-15" @default.
• W3126528925 creator A5000615064 @default.
• W3126528925 creator A5003040604 @default.
• W3126528925 creator A5010992446 @default.
• W3126528925 creator A5012371091 @default.
• W3126528925 creator A5022113326 @default.
• W3126528925 creator A5024047021 @default.
• W3126528925 creator A5027204492 @default.
• W3126528925 creator A5029630690 @default.
• W3126528925 creator A5037946109 @default.
• W3126528925 creator A5039615307 @default.
• W3126528925 creator A5044076082 @default.
• W3126528925 creator A5045018617 @default.
• W3126528925 creator A5045083114 @default.
• W3126528925 creator A5048540733 @default.
• W3126528925 creator A5060018150 @default.
• W3126528925 creator A5065999376 @default.
• W3126528925 creator A5070672255 @default.
• W3126528925 creator A5081111691 @default.
• W3126528925 creator A5088919162 @default.
• W3126528925 date "2021-02-03" @default.
• W3126528925 modified "2023-10-16" @default.
• W3126528925 title "Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors" @default.
• W3126528925 cites W1981814091 @default.
• W3126528925 cites W2052375870 @default.
• W3126528925 cites W2124609050 @default.
• W3126528925 cites W2131947231 @default.
• W3126528925 cites W2144248027 @default.
• W3126528925 cites W2345464298 @default.
• W3126528925 cites W2563046824 @default.
• W3126528925 cites W2610623677 @default.
• W3126528925 cites W2785643516 @default.
• W3126528925 cites W2789588846 @default.
• W3126528925 cites W2794408630 @default.
• W3126528925 cites W2795026792 @default.
• W3126528925 cites W2801069891 @default.
• W3126528925 cites W2803997637 @default.
• W3126528925 cites W2811121118 @default.
• W3126528925 cites W2887249435 @default.
• W3126528925 cites W2900756811 @default.
• W3126528925 cites W2912418732 @default.
• W3126528925 cites W2914335731 @default.
• W3126528925 cites W2919091706 @default.
• W3126528925 cites W2934922729 @default.
• W3126528925 cites W2946962120 @default.
• W3126528925 cites W2948464544 @default.
• W3126528925 cites W2948760318 @default.
• W3126528925 cites W2966967063 @default.
• W3126528925 cites W2982252373 @default.
• W3126528925 cites W2986909458 @default.
• W3126528925 cites W2989421605 @default.
• W3126528925 cites W2990052644 @default.
• W3126528925 cites W2992897657 @default.
• W3126528925 cites W2995057010 @default.
• W3126528925 cites W3001058124 @default.
• W3126528925 cites W3012576932 @default.
• W3126528925 cites W3024940939 @default.
• W3126528925 cites W3036505603 @default.
• W3126528925 cites W3084409519 @default.
• W3126528925 cites W3093537743 @default.
• W3126528925 cites W3112864714 @default.
• W3126528925 cites W3115966630 @default.
• W3126528925 cites W5139590 @default.
• W3126528925 doi "https://doi.org/10.3390/cancers13040585" @default.
• W3126528925 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7913165" @default.
• W3126528925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33546102" @default.
• W3126528925 hasPublicationYear "2021" @default.
• W3126528925 type Work @default.
• W3126528925 sameAs 3126528925 @default.
• W3126528925 citedByCount "24" @default.
• W3126528925 countsByYear W31265289252021 @default.
• W3126528925 countsByYear W31265289252022 @default.
• W3126528925 countsByYear W31265289252023 @default.
• W3126528925 crossrefType "journal-article" @default.
• W3126528925 hasAuthorship W3126528925A5000615064 @default.
• W3126528925 hasAuthorship W3126528925A5003040604 @default.
• W3126528925 hasAuthorship W3126528925A5010992446 @default.
• W3126528925 hasAuthorship W3126528925A5012371091 @default.
• W3126528925 hasAuthorship W3126528925A5022113326 @default.
• W3126528925 hasAuthorship W3126528925A5024047021 @default.
• W3126528925 hasAuthorship W3126528925A5027204492 @default.
• W3126528925 hasAuthorship W3126528925A5029630690 @default.
• W3126528925 hasAuthorship W3126528925A5037946109 @default.
• W3126528925 hasAuthorship W3126528925A5039615307 @default.
• W3126528925 hasAuthorship W3126528925A5044076082 @default.
• W3126528925 hasAuthorship W3126528925A5045018617 @default.
• W3126528925 hasAuthorship W3126528925A5045083114 @default.
• W3126528925 hasAuthorship W3126528925A5048540733 @default.
• W3126528925 hasAuthorship W3126528925A5060018150 @default.
• W3126528925 hasAuthorship W3126528925A5065999376 @default.
• W3126528925 hasAuthorship W3126528925A5070672255 @default.
• W3126528925 hasAuthorship W3126528925A5081111691 @default.
• W3126528925 hasAuthorship W3126528925A5088919162 @default.
• W3126528925 hasBestOaLocation W31265289251 @default.
• W3126528925 hasConcept C104317684 @default.
• W3126528925 hasConcept C121608353 @default.
• W3126528925 hasConcept C126322002 @default.

• next